Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of sunitinib combined with docetaxel versus docetaxel, administered as first-line treatment, in patients with unresectable locally recurrent or metastatic breast cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Docetaxel; Sunitinib

Criteria

Inclusion Criteria:

• Breast cancer with evidence of unresectable locally recurrent, or metastatic disease

• Her-2 negative tumors

Exclusion Criteria:

• Patients for whom docetaxel is contraindicated

• Clinical presentation of inflammatory carcinoma with no other measurable disease